Activation of nuclear factor-κB correlates with MCP-1 expression by human mesangial cells  by Rovin, Brad H. et al.
Kidney International, Vol. 48 (1995), pp. 1263—1271
Activation of nuclear factor-KB correlates with MCP-1 expression
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Activation of nuclear factor-KB correlates with MCP-1 expression by
human mesangial cells. Emerging evidence suggests that mesangial
cell-derived monocyte chemoattractant protein-i (MCP-1) is a potentially
important mediator of glomerular monocyte infiltration. Interleukin-1j3(IL-i) has been found in glomeruli during inflammation, and is a potent
inducer of MCP-1 expression by mesangial cells. Analysis of the promoter
region of the human MCP-1 gene demonstrates several putative binding
sites for transcription activating factors, including recognition elements for
the IL-i-inducible transcription factor, nuclear factor-kappa B (NF-KB).
This study investigated the role of NF-KB in IL-i-induced MCP-1
expression by human mesangial cells. We found that treating mesangial
cells with IL-I resulted in the rapid activation (within 30 mm) and nuclear
translocation of NF-KB. NF-KB activation could be blocked by preventing
the proteolytic degradation of 1KB, the cytoplasmic inhibitor of NF-KB,
with the protease inhibitor tosyl-phe-chioromethylketone (TPCK). Inhi-
bition of NF-KB with TPCK correlated with a dose-dependent reduction
in IL-i-induced MCP-1 mRNA levels. Conversely, raising intracellular
cyclic-AMP levels, or exposing mesangial cells to herbimycin A, treat-
ments that block IL-i-induced MCP-1 mRNA expression, significantly
attenuated NF-KB activation. Finally, blocking the synthesis of one of the
protein subunits of NF-KB with an antisense oligonucleotide decreased
MCP-1 mRNA levels in response to IL-i. These data suggest that MCP-1
gene transcription may be mediated, in part, by the transcription factor
NF-KB.
Although many factors have been postulated to recruit mono-
cytes to the glomerulus during renal injury, monocyte chemoat-
tractant protein-i (MCP-1) is emerging as a potentially important
mediator of monocyte infiltration. MCP-1 is chemotactic for
monocytes but not neutrophils [11. In addition to being a chemo-
tactic factor, MCP-1 activates monocytes [2], and can induce
leukocyte adhesion molecules on endothelial and vascular smooth
muscle cells [3, 4], making it a potent pro-inflammatory molecule.
A role for MCP-1 in glomerulonephritis (GN) is suggested by
recent studies that demonstrated glomerular MCP-1 expression in
experimental and human GN [5, 6]. While the glomerular cell(s)
responsible for MCP-i production in vivo remain to be deter-
mined, in vitro studies using mesangial cells point to the mesan-
gium as a possible source of glomerular MCP-1 [7—9]. Cultured
mesangial cells produce MCP-1 in response to several factors
thought to be involved in glomerular injury. These include the
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inflammatory cytokines interleukin-1f3 (IL-i) and tumor necrosis
factor-a (TNF) [7], immune complexes [10, 11], atherogenic
lipoproteins [12], and thrombin [13].
The intracellular mechanisms leading to mesangial MCP-1 gene
activation in response to exogenous stimuli have not been fully
characterized, although this effect appears to be transcriptionally
regulated [14]. IL-i does not appear to up-regulate MCP-1
through protein kinase C (PKC), and cyclic-AMP (cAMP) nega-
tively modulates the actions of IL-i on MCP-1 in mesangial cells
[15]. We have recently provided evidence that IL-I may induce
MCP-1 expression through a protein tyrosine kinase (PTK)
pathway [15]. To unify these observations, we examined the
known sequence [reviewed in 16, 17] of the MCP-1 5'-flanking
region for potential IL-i-responsive promoter elements. Of par-
ticular interest, the MCP-i gene has several elements that are
homologous to the sequence 5'-GGG(AIG) (CIA!T)T(CiT) (C!
T)CC-3', the consensus binding motif [18] for the transcription
activating factor nuclear factor-kappa B (NF-KB) [16]. NF-KB is
important in the transcriptional activation of genes for proteins
that participate in immune responses, and is inducible in non-
lymphoid cells by IL-i [14, 18]. Additionally, deletion analysis of
the MCP-1 5'-flanking region transfected into tumor cell lines
showed that an NF-KB element is required for cytokine-mediated
reporter gene activity [17]. We thus postulated that NF-xB is
necessary for IL-i-induced MCP-1 gene activation in human
mesangial cells.
To test this hypothesis, we evaluated the effects of preventing
NF-KB activation on IL-i-inducible MCP-1 mRNA expression.
Additionally, the effects of known inhibitors of MCP-i gene
activation on IL-i-inducible NF-KB levels were determined. We
found that blocking NF-KB activation inhibits the up-regulation of
MCP-1 mRNA expression by IL-i. Conversely, inhibitors of
MCP-i mRNA expression also attenuate NF-KB levels. These
data suggest that IL-i-activated MCP-1 gene transcription may be
mediated, in part, by the transcription factor NF-KB.
Methods
Human mesangial cell culture
The procedures used in our laboratory to isolate and charac-
terize human mesangial cells have been described [7]. In this
investigation cells from six different donors were used between
passages 5 and 10. They were grown to confluence in RPMI 1640
containing 10% fetal bovine serum (GIBCO, Grand Island, NY,
USA). Before treating cells with various reagents, the monolayers
were washed three times to remove serum. All subsequent
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incubations were carried out in RPMI 1640 + 0.25% bovine
serum albumin (BSA).
Mesangial cell conditioning
In these experiments mesangial cells were treated with a variety
of reagents chosen to activate or inhibit NF-KB or MCP-1
expression. All reagents were diluted in RPMI 1640 + 0.25% BSA
to achieve the appropriate concentrations. Control monolayers
were treated only with RPMI 1640 + 0.25% BSA; in experiments
using reagents that were solubilized in an organic solvent (DMSO
or ethanol), the media for control monolayers contained these
solvents in the same final concentrations as the experimental
monolayers.
MCP-1 mRNA was up-regulated in mesangial cells with 0.6 to
1.2 ng/mI human rIL-113 (sp. act. 5 X 108 U/mg; Genzyme,
Cambridge, MA, USA), 10 to 50 nM phorbol 12-myristate 13-
acetate (PMA; Sigma Chemical Co., St. Louis, MO, USA), or 2 to
20 ng/ml human rTNF-a (sp. act. 5 X 106 U/mg; gift of Dr. Mark
Wewers, Ohio State University, Columbus, OH, USA), These
concentrations were previously determined to cause significant
induction of MCP-1 [7, 15].
To inhibit NF-KB activation, mesangial cells were pre-treated
with the protease inhibitor tosyl-phe-chloromethylketone (TPCK,
Sigma) for one hour prior to the addition of IL-i, TPCK has been
shown to inhibit IL-i-inducible NF-KB in other cell types [19].
TPCK was used in concentrations of 5 to 50 JLM. In other
experiments, the antioxidant and reported NF-,B inhibitor [20],
pyrrolidinedithiocarbamate (PDTC, Sigma) was tested for its
ability to block mesangial NF-KB activation. Monolayers were
pretreated for one hour with 10 to 90 tM PDTC, as described for
other cells [20]. These reagents did not effect mesangial cell
viability as assessed by trypan blue exclusion or LDH release
(Sigma LDH assay kit #228 —1 0).
Previous work from this laboratory showed that IL-i-induced
MCP-1 mRNA expression could be blocked by either increasing
intracellular cAMP or by pre-treating cells with various PTK
inhibitors [15]. Using protocols we have established [15], intracel-
lular cAMP was raised either by treating mesangial cells with 1
mM 3-isobutyl-1 methyl-xanthine (IBMX, Sigma) for 30 minutes
plus 20 IIM forskolin (Sigma) for the last 10 minutes, or by
pre-incubating cells with 1 mrvi N6,2'-O-dibutyryladenosine 3':S'-
cyclic monophosphate (db-cAMP, Sigma) for 30 minutes. To
block PTK activity, mesangial cells were treated with the PTK
inhibitors genistein (Calbiochem, San Diego, CA, USA), herbi-
mycin A (GIBCO), or tyrphostin B46 (Calbiochem). Cell viability
was not adversely effected by raising cAMP or by these PTK
inhibitors, measured by trypan blue exclusion or LDH release.
Tissue culture media, organic solvents, and cytokines were
found to be virtually endotoxin free (< 0.1 ng/ml) using the
quantitative Limulus amoebocyte lysate assay (M.A. Bioproducts,
Walkersville, MD, USA).
Nuclear protein extraction and electrophoretic mobility shift
analysis (EMSA)
Nuclear proteins were isolated from two confluent 75 cm2 flasks
by a modification [21] of the method outlined by Dingnam,
Lebovitz and Roeder [22]. Nuclear proteins (10 g) were incu-
bated with a double-stranded oligonucleotide (0.2 ng) contain-
ing a tandem repeat of a consensus [18] NF-KB recognition ele-
ment (GIBCO). The underlined bases illustrate the NF-KB motifs
in this oligonucleotide: 5 '-GATCCAAGGGGAC'ITT'CCGCTG-
GGGACTVFCCATG-3'. This was 32P-end labeled with T4
polynucleotide kinase (GIBCO) plus (y-32P)ATP (6000 Ci/mmol;
New England Nuclear, Boston, MA, USA). The binding reaction
was carried out in 25 p1 of buffer (10 mrvi Tris pH 7.5, 100 mM
NaCI, 1 mrvi DTT, 5 mivi EDTA, 4% glycerol, and 2 g poly(dI-
dC)) for 20 minutes prior to electrophoresis on a 6% non-
denaturing polyacrylamide gel in a Tris-Borate-EDTA buffer
system. Dried gels were exposed to Kodak XR5 film (Rochester,
NY, USA) for 4 to 16 hours at —70°C. Specificity of the binding
reaction was confirmed using excess unlabeled oligonucleotide to
compete with labeled probe for binding to the nuclear proteins.
Identification of the nuclear proteins that reacted with this probe
was obtained by pre-incubating the nuclear extracts for 45 minutes
with antibodies (1.5 jig) to the protein subunits of NF-KB, p50
(NF-KB1) or p65 (Re! A) before radiolabeled probe was added.
EMSA was then performed as outlined and the effect of the
antibody on the NF-KB band examined. Rabbit polyclonal anti-
bodies to p50 and p65 were obtained from Santa Cruz Biotech-
nology (Santa Cruz, CA, USA). A rabbit polyclonal antibody to an
unrelated transcription factor (c-fun; Santa Cruz) was used as a
control for non-specific binding.
RNA analysis
Total cellular RNA was isolated from appropriately condi-
tioned mesangial monolayers as we have previously described [7].
RNA was separated on agarose gels and probed for MCP-1
mRNA using a XhoI fragment from p-hJE34 (ATCC, Rockville,
MD, USA) as described [231. Some blots were probed for
fibronectin mRNA using the EcoRI fragment from FN771
(ATCC). The Northern blots were reprobed for glyceraidehyde-
3-phosphate dehydrogenase (GAPD) using a full length human
cDNA probe (CloneTech, Palo Alto, CA, USA) to normalize for
variations in RNA loading. The blots were analyzed after autora-
diography by laser densitometry (Pharmacia LKB Biotechnology,
Piscataway, NJ, USA).
Immunoblotting of mesangial cell lysates
Confluent mesangial cells grown in 100 mm plates were treated
with IL-i. At specified times the cells were washed and disrupted
in lysis buffer (1% NP-40, 20 ms't Tris-HC1, pH 8.0, 137 mri NaCI,
10% glycerol, 1 msi Na3VO4, 2 ms'i EDTA, 1 mi PMSF, 20 jM
leupeptin, 0.15 U/mi aprotinin). Cell proteins were resolved on a
10% SDS-polyacrylamide gel under reducing conditions and
transferred to 0.45 1LM nitrocellulose membranes (Hoeffer, San
Francisco, CA, USA) using an eiectroblotting technique as de-
scribed by Kyhse-Anderson [24]. Membranes were probed for the
NF-,<B inhibitor protein 1KB using a rabbit polyclonal anti-human
1KB antibody (Santa Cruz). Non-immune rabbit IgG served as a
control. The secondary antibody was a biotinylated goat anti-
rabbit IgG (Zymed, San Francisco, CA, USA). The blots were
developed using enhanced chemiluminescence (Amersham, Ar-
lington Heights, IL, USA).
Superoxide anion measurement
Superoxide anion was measured as the superoxide dismutase
inhibitable reduction of ferricytochrome c (Type VI, Sigma) in the
conditioned supernatants from control mesangial cells, or cells
treated with IL-I (0.6 ng/ml), as we have previously described [25].
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Treatment with an antisense olignonucleotide to p65
Antisense and sense oligonucleotides to the 5' end (including
the ATG start site) of the p65 subunit of NF-KB have been
described and shown to inhibit NF-KB-dependent gene expression
[26—28]. Phosphorothioate analogs of the antisense (5'-GGG
GAA CAG TTC GTC CAT GGC-3') and sense (5'-GCC ATG
GAC GAA CTG TIC CCC-3') oligonucleotides were synthesized
by Oligos, Etc (Wilsonville, OR, USA). Because NF-KB is consti-
tutively expressed in the cytoplasm of mesangial cells, it was
necessary to activate this pooi of NF-KB and (presumably)
stimulate new NF-KB synthesis prior to treating cells with the
oligonucleotides. This was accomplished by pre-treating the cells
with IL-i (1.1 ng/ml) for 30 minutes. Cells were washed and fresh
media containing the oligonucleotides was added. After five hours
IL-i was added, and following an overnite incubation, RNA was
isolated and MCP-1 mRNA measured. The incubation was pro-
longed in an effort to further deplete the cells of pre-existing
NF-KB that could be recycled from the nucleus [14].
Results
Activation of NF- in mesangial cells
EMSA of nuclear extracts harvested from untreated (control)
mesangial cells demonstrated little constitutive binding to an
oligonucleotide containing the consensus NF-KB recognition se-
quence (Fig. 1). After IL-i treatment two shifted bands were
identified: a slowly migrating minor band, and an intensely labeled
complex of greater mobility (Fig. 1A). The presence and intensity
of the slowly migrating protein-oligonucleotide complex was
variable between nuclear preparations. The specificity of the
binding reaction was confirmed by the ability of excess unlabeled
NF-B oligonucleotide to inhibit binding (Fig. 1A). Incubation
with an excess of an irrelevant oligonucleotide (containing a
tandem repeat of the AP-1 consensus motif) did not block binding
(Fig. 1A). Similarly, excess oligonucleotide containing an OCT
recognition motif did not prevent binding (not shown). NF-KB
was significantly up-regulated within one hour of IL-i treatment,
and declined over the next two to four hours (Fig. 1B). In other
experiments nuclear NF-KB was detected as early as 30 minutes
after administering IL-i.
To further characterize the nuclear proteins binding to the
NF-KB motif, nuclear extracts were pre-incubated with antibodies
to p65 (Rel A) or p50 (NF-KB1), the protein subunits of the active
NF-KB heterodimer. Incubation with these antibodies, but not
with an antibody to an unrelated transcription factor (c-fun),
further retarded mobility of the labeled oligonucleotide probe,
supershifting activity to the top of the gel (Fig. 1C). This suggests
that the IL-I-induced nuclear binding protein contained p50 and
p65 (that is, active NF-KB).
Similar results were obtained using nuclear extracts from
mesangial cells treated with PMA or TNF, other factors known to
up-regulate MCP-1 expression (Fig. 1D).
Effect of inhibition of NF- ,cB activation on MCP-1 expression
NF-KB is constitutively present in an inactive form in the
cytoplasm where it is bound to the inhibitor protein 1KB [29].
Activation of latent NF-KB is dependent on the disassociation of
1KB from the p50-p65 complex [19]. Once 1KB is removed it is
degraded and NF-KB can translocate to the nucleus and initiate
transcription of NF-,<B dependent genes [19]. IL-i treatment of
mesangial cells caused the disappearance of immunoreactive 1KB
within 15 minutes. This was sustained for approximately one hour
(Fig. 2A). Pretreatment of mesangial cells with the protease
inhibitor TPCK dose-dependently decreased the IL-i-induced
degradation of 1KB (Fig. 2B). TPCK treatment resulted in a
significant attenuation in NF-KB activation (Fig. 3A) that corre-
lated with an inhibition of IL-i-induced MCP-i mRNA levels
(Fig. 3B). To demonstrate that TPCK preferentially inhibits
expression of NF-KB-dependent genes, we examined the effect of
TPCK on fibronectin mRNA. The fibronectin gene is not thought
to be regulated by NF-KB [30]. TPCK (10 tM) had little effect on
the induction of fibronectin mRNA by PMA (4.82 densitometry
area units PMA + TPCK vs. 5.76 area units PMA alone).
Another potential mechanism of inhibiting NF-KB activation is
by reducing oxidant stress [201. The antioxidant PDTC has been
shown to block cytokine or phorbol ester-induced NF-KB activa-
tion in several cell lines [20]. In mesangial cells, however, PDTC
(10 to 90 tM) had no effect on IL-i-induced NF-KB activation
(Fig. 4A). Interestingly, PDTC did attenuate NF-KB activation in
response to TNF (Fig. 4B) and PMA (not shown). Consistent with
the observation that PDTC did not block IL-i-induced NF-KB
activation, cells treated with PDTC showed little inhibition of
IL-i-induced MCP-1 mRNA expression (Fig. 4C). Furthermore,
no superoxide anion production (a measure of oxygen radical
generation) was detected from cells treated with IL-i for up to
one hour.
Effects of inhibitors of MCP-1 mRNA expression on
NF- iB activation
We have previously demonstrated that the effects of IL-i on
mesangial MCP-1 expression can be abrogated by manipulating
certain protein kinase pathways. For example, increasing intracel-
lular cAMP and PKA reduced IL-i-inducible MCP-1 mRNA
levels by 88% [15]. Similarly, the PTK inhibitors herbimycin,
genistein, and tyrphostin blocked IL-i-inducible MCP-i mRNA
with an IC50 of 1.9, 32, and 16.7 LM, respectively [15]. To
determine whether manipulating these protein kinase pathways
affected IL-i-inducible NF-KB, nuclear extracts from mesangial
cells so treated were tested for binding to the NF-KB recognition
element. IL-i-induced NF-KB activity was significantly attenuated
in cells treated with either cAMP agonists (Fig. 5) or cells treated
with herbimycin (Fig. 6). Interestingly, IL-i-induced NF-KB levels
were not affected by genistein in concentrations up to 20 jg/ml or
tyrphostin in concentrations up to 50 LM (Fig. 6). These doses
block MCP-1 mRNA expression by 80% to 90% [15].
Effect of an antisense oligonucleotide to the p65 subunit of NF- KB
on MCP-1 expression
Mesangial cells were treated with an antisense oligonucleotide
to p65 to block synthesis of this component of the NF-KB
heterodimer. Since p65 is necessary for the transactivating effects
of NF-KB, we predicted that inhibiting p65 synthesis would
attenuate IL-i-induced MCP-1 expression if MCP-i gene activa-
tion requires NF-KB. Cells treated with antisense to p65 showed
an average decrease of 38.6% in IL-i-induced MCP-i mRNA
levels, compared to cells that had been treated with an oligonu-
cleotide in the sense orientation (Fig. 7). The fact that the
antisense to p65 only partially inhibited MCP-1 mRNA expression
likely reflects residual pre-formed NF-gB in the cytoplasm that
was still available for IL-i activation, or recycling of NF-xB that
was already in the nucleus [14].
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Fig. 1. Activation of NF-cB in human mesangial cells. Binding activity to an oligonucleotide containing a consensus NF-KB motif was assayed in nuclear extracts
of human mesangial cells using EMSA. A. Cells were treated with media alone (control, C) or IL-i (0.6 ng/ml) for one hour. The large arrowhead indicates
the position of the major NF-KB complex while the small arrowhead indicates the minor complex. The open arrow shows unbound oligonucleotide. To
demonstrate the specificity of binding of the NF-KB oligonucleotide, excess (fold excess indicated) unlabeled NF-KB consensus sequence (specific competitor)
was used to compete with the labeled NF-KB probe for binding to IL-i-induced nuclear proteins. Excess (fold excess indicated) unrelated oligonucleotide
containing the AP-1 binding motif (non-specific oligonucleotide) did not inhibit binding of the radiolabeled NF-KB oligonucleotide. B. Cells were treated with
media alone (control) or IL-i (1.2 ng/ml) for the indicated lengths of time. A 1600-fold excess of unlabeled NE-KB consensus sequence (competitor) was used
to demonstrate the specificity of the retarded bands (arrowheads). Unbound oligonucleotide is indicated by the open arrow. C. Nuclear extracts were isolated
from untreated mesangial cells or cells treated with IL-i (0.6 nglml) for one hour. EMSA was carried out in the absence or presence of antibodies (ap5O and
ap65) to the protein components of the NF-KB heterodimer, or excess (1000-fold) unlabeled NF-KB sequence to serve as a competitor. The arrowheads
indicate the positions of the NE-KB complexes. In the presence of ap5O or ap65 the bands at these positions were attenuated and supershifted activity (small
arrowheads labeled s) were identified near the top of these lanes. An irrelevant antibody (ac-jun) did not supershift these bands. Representative of 4
experiments. D. Nuclear extracts were isolated from untreated (control) cells, or cells treated with PMA (50 nM) or TNF (20 nglml) for one hour. Some extracts
were pre-treated with antibody to p65 (ap65) or p50 (ap5O), while other extracts were treated with a 1600-fold excess of unlabeled probe (competitor), to
demonstrate identity and specificity of the DNA binding protein. TNF + ac-jun represents extracts treated with antibody to an irrelevant nuclear binding
protein. The large and small arrowheads mark the positions of the major and minor NE-KB complexes, respectively, while arrowhead s indicates the position
of complexes supershifted in the presence of ap65 and ap5O. The open arrow indicates unbound oligonucleotide. Representative of 3 experiments.
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Fig. 2. IL-i reduces mesangial 1KB levels; modulation by TPCK A. Mes-
angial cells were untreated (control) or treated with IL-i (0.6 ng/ml) for
the indicated lengths of time (mm). Protein extracts of the mesangial
monolayers were immunoblotted for 1KB (apparent molecular mass 39
kD). Representative of 3 experiments. B. Mesangial cells were untreated
(C), treated with IL-i alone for one hour (IL) or pre-treated with the
indicated concentrations of TPCK (xM) before exposure to IL-I for one
hour. Protein extracts were immunoblotted for 1KB as in A. Representa-
tive of 3 experiments.
Discussion
IL-i is a potent activator of the MCP-1 gene in human
mesangial cells [7]. This may be relevant to glomerular inflamma-
tion in vivo, since both IL-i [31, 321 and MCP-i [6, 331 are found
in glomeruli during GN. The intracellular signals that regulate
mesangial MCP-i expression in response to exogenous stimuli are
not completely characterized. This investigation demonstrated
that activation of the transcription factor NF-KB is necessary for
IL-i-induced MCP-i expression. The evidence supporting this
conclusion may be summarized as follows: (1) IL-i treatment of
mesangial cells rapidly induced nuclear proteins that bound to an
oligonucleotide containing an NF-KB consensus recognition mo-
tif. Two NF-KB protein-oligonucleotide complexes were detected,
as described for a variety of cells [21, 34, 35]. Binding was specific
since it was inhibitable by excess unlabeled NF-KB oligonucleo-
tide, but not by oligonucleotides containing unrelated nuclear
protein binding sequences. Furthermore, these nuclear proteins
were recognized by antibodies to p50 and p65, the protein
subunits that form the active NF-KB heterodimer, but not by an
irrelevant antibody. This suggests that the IL-i-inducible nuclear
factor was authentic NF-KB. (2) The kinetics of NF-KB activation
in response to IL-i (within 30 mm) were consistent with the rapid
(within 1 hr) up-regulation of MCP-i mRNA by this cytokine [7].
(3) Inhibition of NF-KB activation caused a decrease in MCP-1
mRNA expression. TPCK blocked IL-i-induced NF-KB activity
by preventing degradation of 1KB, and caused a dose-dependent
inhibition of IL-i-induced MCP-1 mRNA levels. Additionally, an
antisense oligonucleotide to p65 attenuated IL-I -inducible
MCP-1 expression, presumably by blocking the synthesis of p65
and thus the assembly of new NF-KB. (4) Treating mesangial cells
with cAMP agonists or herbimycin A, inhibitors of IL-I-induced
MCP-1 mRNA expression, also attenuated NF-KB activation.
A recent report demonstrated that the consensus NF-KB ele-
ment 5'-GGGAA1ITTCC-3' located between bp —2612 and
—2603 of the MCP-i 5'-flanking region was necessary for cyto-
kine-induced reporter gene activity in transfected malignant cells
[17]. Mutation of the NF-tcB site completely abrogated the
response to IL-i [171. Our data support these findings using
primary, non-transformed cells, and MCP-i mRNA expression
(rather than a reporter construct) to measure intact gene activity.
Taken together, these two investigations provide compelling
GAPD
Fig. 3. TPCK attenuates IL-i-induced NF-KB activity and mRNA expres-
sion. A. Binding activity to an NF-KB consensus motif was assayed by
EMSA in nuclear extracts from cells that were treated with media alone or
25 xM TPCK for 60 minutes. IL-i (0.6 ng/ml) was then added for one
hour. C represents nuclear extracts from control cells. A 2400-fold excess
of unlabeled NF-KB consensus sequence was used as a competitor to
demonstrate the specificity of the retarded (arrowhead) band. Represen-
tative of 2 experiments. B. Cells were treated with the indicated concen-
trations of TPCK (rM) for 60 minutes prior to the addition of IL-i (0.6
ng/ml). Total cellular RNA was harvested after two hours, and MCP-i
mRNA was measured. The blot was re-probed for GAPD mRNA to
normalize for variations in RNA loading. TPCK blocked IL-i-induced
MCP-i mRNA with an IC50 of 8.8 LM.
evidence that NF-KB is necessary for IL-i-induced MCP-1 gene
expression. To conclusively demonstrate that NF-KB activates
MCP-1 transcription in mesangial cells, transfection studies with
intact or mutated MCP-1 promoter constructs will be required.
Such work is currently underway in our laboratory.
A role for oxygen radicals in mediating NF-KB activation has
been postulated because antioxidants (such as PDTC) can block
NF-KB activation in several cell lines [36]. It has recently been
shown, however, that PDTC does not inhibit NF-KB activation in
all cells or in response to all stimuli [37, 38]. Similarly, we found
PDTC did not block IL-i-induced NF-KB activation in human
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Fig. 4. PDTC does not inhibit IL-i-induced NF-icB orMCP-1 expression in
human mesangial cells. A. Cells were treated with the indicated concen-
tration of PDTC (MM) for one hour prior to the addition of IL-i (1.2
nglml) for one hour. Nuclear proteins were extracted and assayed for
binding activity to the NP-KB motif. C represents extracts from control
cells. A 100-fold excess of unlabeled NP-KB consensus sequence (COM)
was used to demonstrate the specificity of the retarded (arrowheads)
bands. Representative of 4 experiments. B. Cells were pre-treated with the
indicated concentrations of PDTC for one hour followed by the addition
IVIL, of TNF (2 nglml) for one hour. Nuclear extracts were probed for NF-xB.
Some extracts were incubated with antibody to the p50 (*) or p65 (**)
subunits of NP-KB to verify the identity of the TNF-induced nuclear
protein. The supershifted antibody-NP-KB complexes are indicated by
arrowhead s. Representative of 3 experiments. C. Cells were treated with
the indicated concentrations of PDTC (jiM) for one hour, then exposed to
IL-i (0.6 nglml) for three hours. Total cellular RNA was harvested and
MCP-1 mRNA measured. C represents RNA from control cells; IL from
GAPD cells treated with IL-i alone. The blots were reprobed for GAPD mRNA
to normalize for variations in RNA loading. Representative of 3 experi-
ments.
mesangial cells, suggesting that IL-I does not stimulate a PDTC-
sensitive signal transduction factor. In contrast, PDTC did atten-
uate TNF and PMA-induced NF-KB expression. Thus, depending
on the stimulus, different upstream signals may be involved in
activating NP-KB in mesangial cells.
Protein tyrosine phosphorylation may be a mechanism for
mediating the effects of IL-I on NF-KB activation. Supporting this
mechanism, we observed the abrogation of IL-i-induced NP-KB
activity by the PTK inhibitor herbimycin in human mesangial cells.
This effect of herbimycin has also been reported for other cell
types [39, 40]. Consistent with a role for tyrosine phosphorylation,
iL-I has been shown to induce several novel tyrosine phospho-
proteins in mesangial cells [15, 41]. The target of an IL-i-induced
PTK may be 1KB since it contains a consensus site for tyrosine
phosphorylation [42]. Thus it has been proposed that tyrosine
phosphorylation of 1KB may result in its degradation and the
release of active NP-KB [18]. It is interesting that neither genistein
or tyrphostin, the other PTK inhibitors used in this study, blocked
the up-regulation of NF-KB by IL-i. This may reflect a difference
in the ability of these inhibitors to block a PTK(s) involved in
mesangial NP-KB activation. Such a difference was illustrated by a
recent study in which high dose genistein (370 jiM) was found to
attenuate NF-KB activation in lymphocytes, but in the same
experiments herbimyein (12 jiM) was much more effective, com-
pletely blocking NF-KB [40]. Additionally, this dose of gcnistein is
fivefold greater than that used in our investigation. The IC50 of
tyrphostin also depends on the target PTK [43]. Since genistein
and tyrphostin do block induction of MCP-1, they may act at a
step beyond NP-KB activation. A possible mechanism could be
blocking transcription factor (such as activated NP-KB) binding to
A "
Co
nt
ro
l 
Co
nt
ro
l +
 c
o
m
p 
IL
-i 
+
 c
o
m
pe
tit
c 
Co
nt
ro
l +
 h
er
bi
n 
IL
-i 
+
 h
er
bi
m
yc
i 
Co
nt
ro
l +
 ty
rp
ho
 
IL
-i 
+
 ty
rp
ho
st
ir 
Vt
 
Rovin et al: NF-KB and MCP-1 expression 1269
C
.i:5 .
'- >, C
-
E
g
+ o + +
o
C '-
C 0> ..E)0)
E E0 ci> 0
— O).C 0
+ + +
Fig. 5. Increasing intracellular cAMP attenuates IL-I -induced NF- icB acti-
vation. Intracellular cAMP was raised by treating mesangial cells with (A)
IBMX + forskolin (+ lanes) or (B) db-cAMP (1 mM). IL-i (0.6 ng/ml) was
added for one hour and nuclear proteins were harvested. Binding activity
to an NF-KB consensus sequence was measured by EMSA. C represents
nuclear extracts from control cells. To demonstrate specificity of the
retarded band, (A) a 500-, 1000-, or 2000-fold excess of unlabeled NF-KB
binding sequence was used to compete for binding of the labeled probe
(COM 1, 2, and 3, respectively), or (B) a 100-fold excess of unlabeled
NF-KB binding sequence was used as a competitor (COM). Representa-
tive of 2 experiments.
Fig. 6. Herbimycin A attenuates IL-i-induced NF-KB activation. Cells were
pre-treated with (A) herbimycin A (5 /LM) or tyrphostin (50 jtM) for 30
minutes, or (B) herbimycin (5 ILM) or genistein (20 jrglml) for 30 minutes.
IL-i (0.6 nglml) was than added for one hour. CONT represents control
cells not treated with IL-I. Nuclear proteins were isolated and binding
activity to the NF-icB consensus sequence was measured by EMSA
(arrowheads). To confirm specificity, some binding reactions were per-
formed in the presence of (A) a 1600-fold excess or (B) a 1000-fold excess
of unlabeled probe (competitor). Representative of 3 experiments.
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Fig. 7. Antisense to p65 blocks IL-I -induced MCP-1 expression. Cells were
pre-treated with IL-i (1.1 ng/ml) for 30 minutes, washed, and exposed to
sense (S) or antisense (AS) oligonucleotides (50 jiM) top65 for five hours.
IL-i was added and RNA harvested after 20 hours. C represents control
cells that received no IL-I or oligonucleotide. MCP-1 and GAPDH
mRNA were measured. Representative of 3 experiments.
DNA by interfering with DNA topoisomerase enzymes, and thus
preventing gene expression. Genistein and tyrphostin have been
shown to inhibit topoisomerase II and 1, respectively [44, 45].
Increasing intracellular cAMP blocks IL-i induction of mesan-
gial MCP-1 mRNA [15]. This cAMP effect may be mediated
through a reduction in NF-KB activity as shown here. A similar
effect of raising intracellular cAMP on NF-KB levels was recently
observed in mouse mesangial cells treated with TNF or aggre-
gated IgG [351. The effects of raising cAMP in mesangial cells are
in contrast to other cell types where cAMP agonists increase
NF-KB activity [46], and MCP-1 mRNA expression [47]. These
differences suggest that the mechanisms involved in regulating
MCP-1 gene expression are dependent on cell type, and may
provide an explanation for tissue-specific inflammatory responses.
In summary, we have demonstrated that IL-i-induced NF-KB
activity in human mesangial cells correlates with increased MCP-1
gene expression, while inhibition of NF-KB activitycorrelates with
decreased MCP-1 gene expression. These results are consistent
with a functional role for the transcription activating factor NF-gB
in mesangial MCP-1 gene expression. Other investigators found a
similar relationship using TNF-treated mouse mesangial cells
[35]. Protein kinases appear to be important in regulating mesan-
gial NF-KB activity and MCP-1 expression. Our data suggest that
NF-KB is activated through a PTK signalling mechanism, while we
and others [35] have shown that induction of the cAMP-PKA
pathway attenuates nuclear NF-KB levels. These results may be
useful in designing interventions to modulate the transcription of
the pro-inflammatory chemokine MCP-1 during glomerular in-
jury.
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